Patient characteristics
Patient . | Age/sex . | Cancer type . | Prior immunotherapy . | No. IL-2 doses . |
|---|---|---|---|---|
| 1 | 55/M | Melanoma | None | 11 |
| 2 | 58/M | Melanoma | MART vaccine | 11 |
| 3 | 63/M | Melanoma | None | 10 |
| 4 | 40/M | Melanoma | Interferon-α | 9 |
| 5 | 35/M | Melanoma | MART/gp100 vaccine | 9 |
| 6 | 59/F | Kidney | None | 7 |
| 7 | 44/M | Kidney | Anti-CTLA-4 | 9 |
| 8 | 18/M | Melanoma | Interferon-α | 9 |
Patient . | Age/sex . | Cancer type . | Prior immunotherapy . | No. IL-2 doses . |
|---|---|---|---|---|
| 1 | 55/M | Melanoma | None | 11 |
| 2 | 58/M | Melanoma | MART vaccine | 11 |
| 3 | 63/M | Melanoma | None | 10 |
| 4 | 40/M | Melanoma | Interferon-α | 9 |
| 5 | 35/M | Melanoma | MART/gp100 vaccine | 9 |
| 6 | 59/F | Kidney | None | 7 |
| 7 | 44/M | Kidney | Anti-CTLA-4 | 9 |
| 8 | 18/M | Melanoma | Interferon-α | 9 |